A new Phase 2 clinical trial of tesetaxel in men with castrate resistant advanced prostate cancer will be conducted through the Prostate Cancer Clinical Trials Consortium (PCCTC). Tesetaxel, an oral taxane which is in clinical development, will be evaluated for its use as both first- and second-line chemotherapy. […]
The Washington Post has written an article about the funding controversy surrounding the Department of Defense (DOD) Medical Research Programs. I urge everyone to go to the web site and add your comments. Members of congress do read the Washington Post daily. Please go to: The Washington Post It would be a good idea if [...]
I am in Orlando Florida attending the Department of Defense Impact Conference for the Prostate Cancer Research Program (PCRP) This DOD program is among the largest funders of prostate cancer research in the world and what is important is that the funding is designed to move research ideas that are specifically designed to have a [...]
Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
Tomorrow, Wednesday- March 2, I will be joining Dr. Daniel Petrylak for a number of radio interviews about prostate cancer. Dr. Petrylak is a world renowned prostate cancer researcher and clinician. He was the principal investigator in for the development of Taxotere (docetaxel). I anticipate that we will cover a number of different prostate cancer [...]